文献速递炎症性肠病消化内镜

荧光标记维多珠单抗用于可视化炎症性肠病药物分布与黏膜靶细胞

Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
PubMed 文献 · Gut · 2024-08-08

本研究通过43例荧光分子成像操作,在炎症性肠病患者中评估静脉注射荧光标记维多珠单抗(vedo-800CW)的宏观与微观分布及靶细胞。结果显示炎症组织中荧光强度呈剂量依赖性增加,15 mg为最适示踪剂量,且治疗剂量未标记维多珠单抗后信号降低61%提示靶点饱和。荧光显微镜显示维多珠单抗可穿透炎症黏膜并与免疫细胞结合,以浆细胞最为显著。

要点

  • 15 mg vedo-800CW为最适示踪剂量,炎症组织荧光强度高于4.5 mg。
  • 治疗剂量未标记维多珠单抗后荧光信号降低61%,提示炎症组织靶点饱和。
  • 维多珠单抗可穿透炎症黏膜并与免疫细胞结合,以浆细胞最显著。

核心结论

  • 荧光分子成像有望确定药物在炎症靶组织中的局部分布并识别药物靶细胞,为炎症性肠病靶向药物的使用提供新见解。

研究设计与样本

  • 共进行43例荧光分子成像操作,包括内镜期间宏观活体评估及随后宏观和微观离体成像。
  • A阶段患者在内镜前接受静脉注射4.5 mg、15 mg vedo-800CW或不注射示踪剂。
  • B阶段患者在接受未标记的(亚)治疗剂量维多珠单抗后接受15 mg vedo-800CW。
  • 试验注册号:NCT04112212。

主要发现

  • 荧光分子成像定量显示炎症组织中vedo-800CW荧光强度呈剂量依赖性增加,15 mg(153.7 au(132.3-163.7))为最适示踪剂量,与4.5 mg(55.3 au(33.6-78.2))相比p=0.0002。
  • 在治疗剂量未标记维多珠单抗后给予vedo-800CW,荧光信号降低61%,提示炎症组织中靶点饱和。
  • 荧光显微镜和免疫染色显示维多珠单抗穿透炎症黏膜并与多种免疫细胞类型相关,以浆细胞最为显著。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment strategies. We aimed to visualise the macroscopic and microscopic distribution of intravenous injected fluorescently labelled vedolizumab, vedo-800CW, and identify its target cells using fluorescence molecular imaging (FMI). DESIGN: Forty three FMI procedures were performed, which consisted of macroscopic in vivo assessment during endoscopy, followed by macroscopic and microscopic ex vivo imaging. In phase A, patients received an intravenous dose of 4.5 mg, 15 mg vedo-800CW or no tracer prior to endoscopy. In phase B, patients received 15 mg vedo-800CW preceded by an unlabelled (sub)therapeutic dose of vedolizumab. RESULTS: FMI quantification showed a dose-dependent increase in vedo-800CW fluorescence intensity in inflamed tissues, with 15 mg (153.7 au (132.3-163.7)) as the most suitable tracer dose compared with 4.5 mg (55.3 au (33.6-78.2)) (p=0.0002). Moreover, the fluorescence signal decreased by 61% when vedo-800CW was administered after a therapeutic dose of unlabelled vedolizumab, suggesting target saturation in the inflamed tissue. Fluorescence microscopy and immunostaining showed that vedolizumab penetrated the inflamed mucosa and was associated with several immune cell types, most prominently with plasma cells. CONCLUSION: These results indicate the potential of FMI to determine the local distribution of drugs in the inflamed target tissue and identify drug target cells, providing new insights into targeted agents for their use in IBD. TRIAL REGISTRATION NUMBER: NCT04112212.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Gabriëls RY, van der Waaij AM, Linssen MD, et al. Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease. Gut. 2024. PMID: 38580386. doi:10.1136/gutjnl-2023-331696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。